Skip to main content

Correction: The value of periportal hyperintensity sign from gadobenate dimeglumine-enhanced hepatobiliary phase MRI for predicting clinical outcomes in patients with decompensated cirrhosis

The Original Article was published on 27 February 2024

Correction to: Insights into Imaging (2024) 15:64 https://doi.org/10.1186/s13244-024-01629-4

The authors wish to note that in Figure 2a of the original article, the special symbol should instead be “<”.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Songbo Zhao or Li Wang.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cong, L., Deng, Y., Cai, S. et al. Correction: The value of periportal hyperintensity sign from gadobenate dimeglumine-enhanced hepatobiliary phase MRI for predicting clinical outcomes in patients with decompensated cirrhosis. Insights Imaging 15, 117 (2024). https://doi.org/10.1186/s13244-024-01706-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13244-024-01706-8